Compare
Celldex Therapeutics, Inc. vs Insight Molecular Diagnostics Inc. vs Biomerica Inc vs Anbio Biotechnology
| Latest fiscal year | Celldex Therapeutics, Inc. CLDX | Insight Molecular Diagnostics Inc. IMDX | Biomerica Inc BMRA | Anbio Biotechnology NNNN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-05-31 | 2025-12-31 |
| Revenue | $1.54M | $4.05M | $4.45M | $8.65M |
| Revenue growth (YoY) | -78.0% | +115.6% | -16.2% | +5.6% |
| Gross margin | 87.1% (computed) | 56.7% | 8.1% | 87.2% |
| Operating margin | n/m | n/m | -119.5% | 66.7% |
| Net margin | n/m | n/m | -84.8% | 74.1% |
| Net income | -$258.76M | -$50.22M | -$3.77M | $6.40M |
| EPS (Diluted) | -$3.90 | -$1.65 | -$1.30 | $0.15 |
| Operating cash flow | -$210.94M | -$22.18M | -$3.42M | -$6.74M |
| Free cash flow | -$213.66M | -$25.37M | n/a | n/a |
| Cash & equivalents | $28.87M | $11.58M | $1.31M | $7.77M |
| Total assets | $582.98M | $25.76M | $6.76M | $30.24M |
| Total liabilities | $55.82M | $57.22M | $4.13M | $87.8K |
| Shareholders' equity | $527.16M | -$31.46M | $2.63M | $30.16M |
| Return on year-end equity | -49.1% | n/a | -143.5% | 21.2% |
| Shares outstanding | 66.55M | 28.68M | 3.20M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Celldex Therapeutics, Inc. | Insight Molecular Diagnostics Inc. | Biomerica Inc | Anbio Biotechnology |
|---|---|---|---|---|
| Latest | $1.54M Ended 2025-12-31 | $4.05M Ended 2025-12-31 | $4.45M Ended 2026-05-31 | $8.65M Ended 2025-12-31 |
| 1 year earlier | $7.02M Ended 2024-12-31 | $1.88M Ended 2024-12-31 | $5.31M Ended 2025-05-31 | $8.19M Ended 2024-12-31 |
| 2 years earlier | $6.88M Ended 2023-12-31 | $1.50M Ended 2023-12-31 | $5.42M Ended 2024-05-31 | $6.71M Ended 2023-12-31 |
| 3 years earlier | $2.36M Ended 2022-12-31 | $958.0K Ended 2022-12-31 | $5.34M Ended 2023-05-31 | $23.54M Ended 2022-12-31 |
| 4 years earlier | $4.65M Ended 2021-12-31 | $2.20M Ended 2021-12-31 | $18.87M Ended 2022-05-31 | n/a |